Latest News and Press Releases

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology ...

Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64 on February 11, 2022 and a 65% premium to...

Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as...

RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and...

Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of...

RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...

RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic...

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Virtual Event on October 14, 2021 RALEIGH, N.C., Sept. 30, 2021 ...

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults ...

RALEIGH, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic...